Quantcast

Surveyed Retinal Specialists Are Receptive to Ophthotech’s Fovista, In line with a Moderate to High Unmet Need for Greater Vision Gains in Wet Age-Related Macular Degeneration

March 12, 2014

Surveyed U.S. Payers Look for Substantial Delivery Achievements for Inclusion of New Agents in Formularies, According to Findings from Decision Resources Group

BURLINGTON, Mass., March 12, 2014 /PRNewswire/ — Decision Resources Group finds that surveyed U.S. and European retinal specialists ascribe a moderate to high unmet need for wet age-related macular degeneration (AMD) therapies that improve visual acuity. In line with this finding, surveyed U.S. retinal specialists expect that they would prescribe Ophthotech’s Fovista to 25 percent of their wet AMD patients. Fovista is an adjunctive, anti-platelet-derived growth factor that is being developed with the aim of improving visual acuity over monotherapy with existing anti-vascular endothelial growth factor (VEGF) standards of care.

http://photos.prnewswire.com/prnvar/20130103/MM36768LOGO

Other key findings from the DecisionBase report entitled Wet Age-Related Macular Degeneration: How Receptive Are Retinal Specialists and Payers to Emerging Therapies Offering Vision Improvements or Greater Dosing Convenience?:

    --  Eylea and Lucentis: Eylea (Regeneron/Bayer HealthCare) achieves the
        position of current clinical gold standard in Decision Resources Group's
        proprietary drug comparator model, thanks to physician perception of its
        less frequent dosing relative to market leader Lucentis
        (Roche/Genentech/Novartis).
    --  Unmet need: Regardless of the incremental delivery benefit offered by
        Eylea, surveyed U.S. and European retinal specialists indicate that
        dosing frequency improvements remain an area of moderate to high unmet
        need in wet AMD.
    --  Formulary inclusion: Surveyed managed care organization pharmacy
        directors, however, appear disinclined to include new agents offering
        once every three months dosing on formulary when priced at a premium to
        current agents.

Comments from Decision Resources Group Analyst Nadja Rozovsky, Ph.D.:

    --  "With vision maintained and at times improved in the majority of
        patients treated with anti-VEGF therapies, interviewed experts highlight
        the need for new therapies that would yield greater gains in visual
        acuity, and clinical trial data suggest that the emerging therapy
        Fovista may partially fulfill this opportunity. Moreover, Decision
        Resources Group's adaptive choice-based conjoint analysis for wet AMD
        indicates a high prescribing likelihood among surveyed U.S. retinal
        specialists for a target product profile similar to that of Fovista."
    --  "Surveyed U.S. payers do not appear receptive to wet AMD therapies that
        offer only delivery frequency improvements, yet they are willing to
        include on formularies wet AMD therapies with lower risk of serious
        ocular side effects. Future wet AMD therapies offering less-invasive
        routes of administration, such as Ohr Pharmaceutical's squalamine eye
        drops, may be clinically differentiated not only on delivery convenience
        but also on safety by offering a potential reduction in the risk of
        serious delivery-related ocular side effects."

Upcoming webinar:

    --  Media members are welcome to attend our upcoming webinar based on this
        report entitled Emerging Wet AMD Treatments: How Receptive Are Retinal
        Specialists and Payers to Therapies Offering Greater Dosing Convenience
        or Vision Improvements? This presentation will be held on Wednesday,
        March 26, 2014. For more information, please contact Christopher Comfort
        at ccomfort@dresourcesgroup.com.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group

Christopher Comfort

781-993-2597

ccomfort@dresourcesgroup.com

Logo – http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group


Source: PR Newswire



comments powered by Disqus